
Cigna (CI) Stock Forecast & Price Target
Cigna (CI) Analyst Ratings
Bulls say
Cigna Group is strategically positioned to capitalize on the anticipated $100 billion biosimilars market by 2030, enhancing its growth potential within the pharmacy benefit management arena. The company is expected to generate double-digit savings on GLP-1 net cost developments for its employer clients, further increasing its attractiveness to current and prospective customers. Additionally, the build-out of Evernorth is projected to offset earnings headwinds from economic downturns, as the end markets for this segment demonstrate greater resilience under adverse conditions.
Bears say
The negative outlook on Cigna Group's stock is primarily influenced by several fundamental risks, including potential inaccuracies in pricing and managing healthcare cost trends, which could adversely affect profitability. Additionally, ongoing regulatory scrutiny of pharmacy benefit managers (PBMs) presents a significant uncertainty, potentially delaying client retention and growth initiatives, particularly for the Evernorth segment. Furthermore, macroeconomic factors such as rising unemployment could lead to declines in commercial membership, further straining the company’s financial performance.
This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.
Cigna (CI) Analyst Forecast & Price Prediction
Start investing in Cigna (CI)
Order type
Buy in
Order amount
Est. shares
0 shares